Will people with acute pain want a new painkiller whose list price is $15.50 a pill when a generic prescription drug is at ...
Nandini Piramal is a member of the Board of Directors at the Piramal Group of Companies, a Rs 9,087 crore conglomerate. She ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
Journavx is the first and only approved non-opioid oral painkiller and the first new class of pain medicine approved in more ...
BMO Capital analyst Evan Seigerman raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $545 from $520 and keeps an Outperform ...
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
Today, companies like TVS Motor Company, Hindustan Zinc, Hyundai Motor India, GMR Airports, Bajaj Auto, Cipla, Piramal Pharma ...